These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 12094551)
1. DNA topoisomerase II as a target for cancer chemotherapy. Walker JV; Nitiss JL Cancer Invest; 2002; 20(4):570-89. PubMed ID: 12094551 [No Abstract] [Full Text] [Related]
2. Topoisomerase II inhibitors--teaching old dogs new tricks. Sharma S Cancer Invest; 2002; 20(4):596-7. PubMed ID: 12094555 [No Abstract] [Full Text] [Related]
3. Culprit and victim -- DNA topoisomerase II. Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686 [TBL] [Abstract][Full Text] [Related]
4. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S; De Jong S; De Vries EG; Mulder NH Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715 [TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? Vasey PA; Kaye SB Br J Cancer; 1997; 76(11):1395-7. PubMed ID: 9400932 [No Abstract] [Full Text] [Related]
6. DNA topoisomerase expression in tumors--a novel target for chemotherapy. Rubin EH Hum Pathol; 2000 Jun; 31(6):631-2. PubMed ID: 10872653 [No Abstract] [Full Text] [Related]
7. Alchemix, p53 and topoisomerase. Grand RJ; Stewart GS Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618 [No Abstract] [Full Text] [Related]
8. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]. Tsunoda T Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938 [No Abstract] [Full Text] [Related]
10. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. Chen W; Qiu J; Shen YM Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142 [TBL] [Abstract][Full Text] [Related]
11. Iridoids as DNA topoisomerase I poisons. Gálvez M; Martín-Cordero C; Ayuso MJ J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835 [TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer. Cunningham JM; Francis GE; Holland MJ; Pirollo KF; Chang EH Br J Cancer; 1991 Jan; 63(1):29-36. PubMed ID: 1846552 [TBL] [Abstract][Full Text] [Related]
13. Catalytic topoisomerase II inhibitors in cancer therapy. Larsen AK; Escargueil AE; Skladanowski A Pharmacol Ther; 2003 Aug; 99(2):167-81. PubMed ID: 12888111 [TBL] [Abstract][Full Text] [Related]
14. Yeast systems for demonstrating the targets of anti-topoisomerase II agents. Nitiss JL; Nitiss KC Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243 [No Abstract] [Full Text] [Related]
16. Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Bailly C Chem Rev; 2012 Jul; 112(7):3611-40. PubMed ID: 22397403 [No Abstract] [Full Text] [Related]
17. From DNA damage to G2 arrest: the many roles of topoisomerase II. Larsen AK; Escargueil AE; Skladanowski A Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724 [TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II as a potential factor in drug resistance of human malignancies. Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236 [TBL] [Abstract][Full Text] [Related]
20. Cancer resistance to type II topoisomerase inhibitors. Pilati P; Nitti D; Mocellin S Curr Med Chem; 2012; 19(23):3900-6. PubMed ID: 22788766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]